Varinrak Thanya, Poolperm Pichayanut, Sawada Takuo, Sthitmatee Nattawooti
a Faculty of Veterinary Medicine , Chiang Mai University , Chiang Mai , Thailand.
b Laboratory of Veterinary Microbiology , Nippon Veterinary and Life Science University , Tokyo , Japan.
Avian Pathol. 2017 Oct;46(5):515-525. doi: 10.1080/03079457.2017.1321105. Epub 2017 May 26.
A previous study demonstrated that a recombinant outer membrane protein H (rOmpH)-based intranasal fowl cholera vaccine elicited efficient homologous protection against the Pasteurella multocida strain X-73 (A:1) in chickens. The present study aimed to determine the cross-protectivity against heterologous P. multocida strains. The rOmpH was purified via electroelution and formulated with two kinds of adjuvants. The vaccine formulations in a total volume of 100 µl were 100 µg rOmpH with 3 µg of Escherichia coli enterotoxin B or 10 µg of CpG ODN2007. Chickens were assigned to three experimental groups depending on bacterial strain challenge exposure as well as three control groups. The chickens were immunized intranasally three times at three-week intervals. Challenge exposures were conducted by inoculation with homologous strain X-73 or heterologous strains P-1059 (A:3) or P-1662 (A:4) at four weeks after the final immunization. The specific antibody against rOmpH was produced in vaccinated birds. Sera IgY and secretory IgA antibody titres were significantly increased (P < 0.05) post-immunization. The stimulation index values of the vaccinated groups were significantly different from stimulation index values of the non-vaccinated groups (P < 0.05). Chicken survival rates after exposure to avian P. multocida strains ranged from 70% to 100%. There was no significant difference in protection between two kinds of adjuvants in vaccine formulations. Statistical analysis indicated no significant differences in protection among avian P. multocida strains challenge exposure. We conclude that an in-house rOmpH-based intranasal fowl cholera vaccine produced efficient cross-protectivity against heterologous strains of P. multocida.
先前的一项研究表明,基于重组外膜蛋白H(rOmpH)的鼻内禽霍乱疫苗可在鸡中引发针对多杀性巴氏杆菌X-73株(A:1)的有效同源保护。本研究旨在确定针对异源多杀性巴氏杆菌菌株的交叉保护作用。通过电洗脱法纯化rOmpH,并与两种佐剂配制。总体积为100 μl的疫苗制剂为含有3 μg大肠杆菌肠毒素B或10 μg CpG ODN2007的100 μg rOmpH。根据细菌菌株攻毒暴露情况,将鸡分为三个实验组以及三个对照组。鸡每隔三周进行三次鼻内免疫。在最后一次免疫后四周,通过接种同源菌株X-73或异源菌株P-1059(A:3)或P-1662(A:4)进行攻毒暴露。接种疫苗的鸡产生了针对rOmpH的特异性抗体。免疫后血清IgY和分泌型IgA抗体滴度显著升高(P < 0.0
5)。接种组的刺激指数值与未接种组的刺激指数值有显著差异(P < 0.05)。暴露于禽多杀性巴氏杆菌菌株后的鸡存活率在70%至100%之间。疫苗制剂中两种佐剂在保护作用方面无显著差异。统计分析表明,禽多杀性巴氏杆菌菌株攻毒暴露之间的保护作用无显著差异。我们得出结论,一种自制的基于rOmpH的鼻内禽霍乱疫苗对异源多杀性巴氏杆菌菌株产生了有效的交叉保护作用。